These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 22836783)

  • 21. Increased risk for atypical fractures associated with bisphosphonate use.
    Lee S; Yin RV; Hirpara H; Lee NC; Lee A; Llanos S; Phung OJ
    Fam Pract; 2015 Jun; 32(3):276-81. PubMed ID: 25846215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bisphosphonates and hip and nontraumatic subtrochanteric femoral fractures in the Veterans Health Administration.
    Safford MM; Barasch A; Curtis JR; Outman R; Saag K
    J Clin Rheumatol; 2014 Oct; 20(7):357-62. PubMed ID: 25275761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence, risk factors, and fracture healing of atypical femoral fractures: a multicenter case-control study.
    Lim SJ; Yeo I; Yoon PW; Yoo JJ; Rhyu KH; Han SB; Lee WS; Song JH; Min BW; Park YS
    Osteoporos Int; 2018 Nov; 29(11):2427-2435. PubMed ID: 30039251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fractures.
    Napoli N; Schwartz AV; Palermo L; Jin JJ; Wustrack R; Cauley JA; Ensrud KE; Kelly M; Black DM
    J Clin Endocrinol Metab; 2013 Feb; 98(2):659-67. PubMed ID: 23345099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features.
    Giusti A; Hamdy NA; Dekkers OM; Ramautar SR; Dijkstra S; Papapoulos SE
    Bone; 2011 May; 48(5):966-71. PubMed ID: 21195812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Atypical femoral fractures and bisphosphonates treatment: is it a risk factor?].
    Geada N; Mafra I; Barroso R; Franco J
    Acta Med Port; 2014; 27(6):704-9. PubMed ID: 25641284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy.
    Lo JC; Hui RL; Grimsrud CD; Chandra M; Neugebauer RS; Gonzalez JR; Budayr A; Lau G; Ettinger B
    Bone; 2016 Apr; 85():142-7. PubMed ID: 26769007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The outcome of surgically treated femur fractures associated with long-term bisphosphonate use.
    Weil YA; Rivkin G; Safran O; Liebergall M; Foldes AJ
    J Trauma; 2011 Jul; 71(1):186-90. PubMed ID: 21610533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Symptomatic atypical femoral fractures are related to underlying hip geometry.
    Taormina DP; Marcano AI; Karia R; Egol KA; Tejwani NC
    Bone; 2014 Jun; 63():1-6. PubMed ID: 24565751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Racial/ethnic differences in hip and diaphyseal femur fractures.
    Lo JC; Zheng P; Grimsrud CD; Chandra M; Ettinger B; Budayr A; Lau G; Baur MM; Hui RL; Neugebauer R
    Osteoporos Int; 2014 Sep; 25(9):2313-8. PubMed ID: 24964891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical characteristics of patients with hip fractures in typical locations and atypical femoral fractures.
    Velasco S; Kim S; Bleakney R; Jamal SA
    Arch Osteoporos; 2014; 9():171. PubMed ID: 24481776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence and medical management of bisphosphonate-associated atypical femoral fractures in a major trauma centre: a retrospective observational study.
    Eisenstein N; Kasavkar G; Bhavsar D; Khan FS; Paskins Z
    BMC Musculoskelet Disord; 2017 Jan; 18(1):29. PubMed ID: 28114975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: sensitivity and trim and fill studies.
    Liu J; Zhang HX; Lu XX; Hu JJ; Deng LF
    Genet Test Mol Biomarkers; 2014 Feb; 18(2):117-22. PubMed ID: 24205872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiographic Changes and Fracture in Patients Having Received Bisphosphonate Therapy for ≥ 5 Years at a Single Institution.
    Ernat J; Song D; Fazio M; Lindell K; Orchowski J
    Mil Med; 2015 Dec; 180(12):1214-8. PubMed ID: 26633664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atypical femur fractures.
    Tyler W; Bukata S; O'Keefe R
    Clin Geriatr Med; 2014 May; 30(2):349-59. PubMed ID: 24721373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.
    Shane E; Burr D; Abrahamsen B; Adler RA; Brown TD; Cheung AM; Cosman F; Curtis JR; Dell R; Dempster DW; Ebeling PR; Einhorn TA; Genant HK; Geusens P; Klaushofer K; Lane JM; McKiernan F; McKinney R; Ng A; Nieves J; O'Keefe R; Papapoulos S; Howe TS; van der Meulen MC; Weinstein RS; Whyte MP
    J Bone Miner Res; 2014 Jan; 29(1):1-23. PubMed ID: 23712442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis.
    Gedmintas L; Solomon DH; Kim SC
    J Bone Miner Res; 2013 Aug; 28(8):1729-37. PubMed ID: 23408697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diaphyseal femur fractures associated with bisphosphonate use.
    Graham J; Irgit K; Smith WR; Bowen TR
    Acta Orthop Traumatol Turc; 2013; 47(4):255-60. PubMed ID: 23999513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis.
    Abrahamsen B; Eiken P; Eastell R
    J Clin Endocrinol Metab; 2010 Dec; 95(12):5258-65. PubMed ID: 20843943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone Formation Parameters of the Biopsied Ilium Differ between Subtrochanteric and Diaphyseal Atypical Femoral Fractures in Bisphosphonate-Treated Patients.
    Kondo N; Fukuhara T; Watanabe Y; Miyasaka D; Yamamoto N; Sato H; Wada Y; Nakatsue T; Fujisawa J; Sakuma M; Imai N; Yoda T; Narita I; Endo N
    Tohoku J Exp Med; 2017 Dec; 243(4):247-254. PubMed ID: 29212985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.